Tiago Fauth
Stock Analyst at Wells Fargo
(3.04)
# 1,081
Out of 5,176 analysts
145
Total ratings
40.91%
Success rate
0.69%
Average return
Main Sectors:
Stocks Rated by Tiago Fauth
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Maintains: Overweight | $171 → $217 | $148.31 | +46.32% | 9 | Oct 31, 2025 | |
| WVE Wave Life Sciences | Maintains: Overweight | $21 → $18 | $12.30 | +46.34% | 4 | Sep 4, 2025 | |
| UTHR United Therapeutics | Maintains: Equal-Weight | $295 → $414 | $541.60 | -23.56% | 7 | Sep 3, 2025 | |
| MNKD MannKind | Maintains: Overweight | $9 → $10 | $2.28 | +338.60% | 2 | Sep 3, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $79 → $73 | $66.75 | +9.37% | 5 | Aug 20, 2025 | |
| LQDA Liquidia | Maintains: Overweight | $25 → $31 | $36.61 | -15.32% | 3 | Aug 13, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $333 → $395 | $328.70 | +20.17% | 7 | Aug 1, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $88 → $65 | $19.85 | +227.46% | 8 | Jul 10, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $67 → $76 | $71.61 | +6.13% | 1 | Jun 30, 2025 | |
| SVRA Savara | Maintains: Overweight | $8 → $7 | $5.28 | +32.58% | 2 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $112 → $101 | $31.06 | +225.18% | 4 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $3 | $1.30 | +130.77% | 2 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $26 | $11.34 | +129.28% | 6 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $17 | $14.43 | +17.81% | 1 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $75 | $62.55 | +19.90% | 1 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $89 | $220.90 | -59.71% | 16 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $51 | $28.35 | +79.89% | 3 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $120 | $55.59 | +115.87% | 7 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $4 | $24.76 | -83.84% | 4 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $2.92 | +379.45% | 4 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $300 | $69.97 | +328.76% | 5 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $26 | $8.55 | +204.09% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $28 | $3.39 | +725.96% | 7 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $81 | $17.72 | +357.11% | 11 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8 | $0.16 | +4,960.09% | 5 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $1.43 | +879.02% | 2 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $34 | $2.04 | +1,566.67% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $42.79 | -32.22% | 1 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $1.62 | +702.47% | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $13 | $2.32 | +460.34% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2.5 → $2 | $0.94 | +112.70% | 4 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $297 → $340 | $697.05 | -51.22% | 3 | Dec 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $265 → $259 | $353.93 | -26.82% | 1 | Apr 28, 2021 |
Insmed
Oct 31, 2025
Maintains: Overweight
Price Target: $171 → $217
Current: $148.31
Upside: +46.32%
Wave Life Sciences
Sep 4, 2025
Maintains: Overweight
Price Target: $21 → $18
Current: $12.30
Upside: +46.34%
United Therapeutics
Sep 3, 2025
Maintains: Equal-Weight
Price Target: $295 → $414
Current: $541.60
Upside: -23.56%
MannKind
Sep 3, 2025
Maintains: Overweight
Price Target: $9 → $10
Current: $2.28
Upside: +338.60%
PTC Therapeutics
Aug 20, 2025
Maintains: Overweight
Price Target: $79 → $73
Current: $66.75
Upside: +9.37%
Liquidia
Aug 13, 2025
Maintains: Overweight
Price Target: $25 → $31
Current: $36.61
Upside: -15.32%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Equal-Weight
Price Target: $333 → $395
Current: $328.70
Upside: +20.17%
Ultragenyx Pharmaceutical
Jul 10, 2025
Maintains: Overweight
Price Target: $88 → $65
Current: $19.85
Upside: +227.46%
BridgeBio Pharma
Jun 30, 2025
Maintains: Overweight
Price Target: $67 → $76
Current: $71.61
Upside: +6.13%
Savara
May 28, 2025
Maintains: Overweight
Price Target: $8 → $7
Current: $5.28
Upside: +32.58%
Mar 21, 2025
Maintains: Overweight
Price Target: $112 → $101
Current: $31.06
Upside: +225.18%
Mar 4, 2025
Maintains: Equal-Weight
Price Target: $4 → $3
Current: $1.30
Upside: +130.77%
Feb 27, 2025
Maintains: Overweight
Price Target: $28 → $26
Current: $11.34
Upside: +129.28%
Feb 20, 2025
Maintains: Overweight
Price Target: $18 → $17
Current: $14.43
Upside: +17.81%
Aug 22, 2024
Initiates: Overweight
Price Target: $75
Current: $62.55
Upside: +19.90%
Jun 14, 2023
Assumes: Neutral
Price Target: $89
Current: $220.90
Upside: -59.71%
Jun 14, 2023
Assumes: Outperform
Price Target: $51
Current: $28.35
Upside: +79.89%
Jun 14, 2023
Assumes: Outperform
Price Target: $120
Current: $55.59
Upside: +115.87%
May 23, 2023
Reiterates: Underperform
Price Target: $4
Current: $24.76
Upside: -83.84%
May 16, 2023
Reiterates: Outperform
Price Target: $14
Current: $2.92
Upside: +379.45%
May 16, 2023
Reiterates: Outperform
Price Target: $300
Current: $69.97
Upside: +328.76%
May 11, 2023
Reiterates: Outperform
Price Target: $26
Current: $8.55
Upside: +204.09%
May 5, 2023
Maintains: Outperform
Price Target: $34 → $28
Current: $3.39
Upside: +725.96%
May 5, 2023
Maintains: Neutral
Price Target: $70 → $81
Current: $17.72
Upside: +357.11%
Mar 24, 2023
Reiterates: Neutral
Price Target: $8
Current: $0.16
Upside: +4,960.09%
Mar 23, 2023
Reiterates: Outperform
Price Target: $14
Current: $1.43
Upside: +879.02%
Mar 10, 2023
Maintains: Outperform
Price Target: $38 → $34
Current: $2.04
Upside: +1,566.67%
Jan 26, 2023
Initiates: Outperform
Price Target: $29
Current: $42.79
Upside: -32.22%
Dec 16, 2022
Initiates: Outperform
Price Target: $13
Current: $1.62
Upside: +702.47%
Nov 18, 2022
Downgrades: Neutral
Price Target: $25 → $13
Current: $2.32
Upside: +460.34%
May 13, 2022
Maintains: Underperform
Price Target: $2.5 → $2
Current: $0.94
Upside: +112.70%
Dec 20, 2021
Maintains: Neutral
Price Target: $297 → $340
Current: $697.05
Upside: -51.22%
Apr 28, 2021
Maintains: Outperform
Price Target: $265 → $259
Current: $353.93
Upside: -26.82%